PTEN-deficient breast cancers have worse disease-free and overall survival rates [135] and have been linked to reduced efficacy of CDK4/6 inhibitors and PI3K/AKT/mTOR pathway inhibitors [136]. This evidence concerns the gene CDK4 and breast carcinoma.